This morning, PeregrinePharmaceuticals released additional details regarding its revised analysis of bavituximab in non-small cell lung cancer. Today's release comes less than a week after investors totally misinterpreted clinical data on the drug used in pancreatic cancer, initially bidding up shares before a sharp sell-off later in the day. As Brenton Flynn outlines in the video below, this time around the investor reaction has been much more rational.
The ying to Peregrine's yang?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today -- along with a free year of updates -- simply click here now.
The article Peregrine Investors: Once Bitten, Twice Shy originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.